Johnson & Johnson (NYSE:JNJ) researches, develops, manufactures and sells various products in the health care field worldwide ...

AD, The most common inflammatory skin disorder worldwide, is a highly heterogeneous condition with current treatments that do ...

Presentation Operator Good morning and welcome to Johnson and Johnson's fourth quarter 2024 earnings conference call. All ...

Q4 2024 Earnings Call Transcript January 22, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.04, ...

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...

HistoSonics, a medical device company backed by Johnson & Johnson’s venture capital arm, is exploring the possibility of a U.S. initial ...

Johnson & Johnson (NYSE ... and the acquisition adds an important commercial product for a growth-starved big pharma company like J&J, and I think that the early-stage pipeline could bring upside ...

Leerink Partners analyst Marc Goodman maintained a Buy rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target ...

Johnson & Johnson, founded in 1886, makes and sells medical devices, pharmaceuticals, and consumer health products. Headquartered in New Brunswick, N.J., the company operates over 250 subsidiary ...

Johnson & Johnson (NYSE: JNJ) traded lower on Wednesday after the MedTech giant disclosed a temporary pause in U.S. cases treated with its Varipulse Pulsed Field Ablation Platform, which targets ...